StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) in a research report released on Thursday. The firm issued a buy rating on the biotechnology company’s ...

Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Aquestive Therapeutics in a ...

We recently published a list of 12 Best Multibagger Stocks to Buy in 2025. In this article, we are going to take a look at ...

Knight Therapeutics Inc. (TSX: GUD) ("Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2024 financial results on Thursday, March 20, ...

Follow live coverage as Stoke City face Blackburn Rovers in the Championship today. An increasingly competitive second tier ...

Egg prices again reached a record high in February, as the bird flu continues to run rampant and Easter and Passover approach. The latest monthly Consumer Price Index showed a ...

Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA ...

Soldiers of 11th Engineer Battalion, 2nd Infantry Division, ROK-US Combined Division, had the opportunity to observe a unique ...

The Eighth Army began its portion of Freedom Shield 2025 on March 9, 2025. Freedom Shield is an 11-day exercise ...

Officers, 10% owners, and other insiders have shelled out more than $10 million on each of these four biotech stocks in the ...

MONTREAL, March 11, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has entered into a ...